Nishida Koyo, Okazaki Madoka, Sakamoto Ryuichi, Inaoka Natsuko, Miyake Hideaki, Fumoto Shintaro, Nakamura Junzo, Nakashima Mikiro, Sasaki Hitoshi, Kakumoto Mikio, Sakaeda Toshiyuki
Department of Clinical Pharmacy, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan.
Biol Pharm Bull. 2007 Sep;30(9):1763-7. doi: 10.1248/bpb.30.1763.
We compared the pharmacokinetics of model compounds with different elimination processes between hypothermic and normothermic rats, to obtain basic information concerning drug therapy during hypothermia. Male Wistar rats were anesthetized with sodium pentobarbital and kept at temperatures of 37 degrees C (normothermic group) by heat lamp, and 32 degrees C or 28 degrees C (hypothermic group) by external cooling. We chose phenolsulfonphthalein (PSP), indocyanine green (ICG) and fluorescein isothiocyanate (FITC)-dextran (FD-4, Mw 4400) as model compounds to determine changes in clearance pathways during hypothermia therapy. The plasma concentrations of PSP as biliary, urinary and metabolic elimination type were increased significantly in the hypothermic group (32 degrees C, 28 degrees C) after i.v. administration at a dose of 1 mg, compared to the normothermic group (37 degrees C). Each PSP clearance (bile, urine and metabolites) in the hypothermic group was decreased, suggesting an influence of hypothermia on the active elimination process. The decreasing tendency was marked at a temperature of 28 degrees C. Moreover, the plasma concentrations of ICG as the biliary excretion type after i.v. administration to the hypothermic rats at a dose of 1 mg were higher with more than 50% decrease in the total body clearance compared to normothermic rats. On the other hand, there was almost no difference in the i.v. pharmacokinetics of FD-4 as the urinary excretion type between 37 degrees C and 32 degrees C. However, renal clearance of FD-4 was significantly decreased at a temperature of 28 degrees C. Accordingly, the change in pharmacokinetics of a drug in the hypothermic group could differ with the elimination processes.
我们比较了低温和常温大鼠体内具有不同消除过程的模型化合物的药代动力学,以获取有关低温期间药物治疗的基础信息。雄性Wistar大鼠用戊巴比妥钠麻醉,通过加热灯保持在37℃(常温组),通过外部冷却保持在32℃或28℃(低温组)。我们选择酚红(PSP)、吲哚菁绿(ICG)和异硫氰酸荧光素(FITC)-葡聚糖(FD-4,分子量4400)作为模型化合物,以确定低温治疗期间清除途径的变化。静脉注射1mg剂量后,低温组(32℃、28℃)中作为胆汁、尿液和代谢消除类型的PSP血浆浓度与常温组(37℃)相比显著升高。低温组中每种PSP清除率(胆汁、尿液和代谢物)均降低,表明低温对主动消除过程有影响。在28℃时这种降低趋势明显。此外,低温大鼠静脉注射1mg剂量后,作为胆汁排泄类型的ICG血浆浓度较高,与常温大鼠相比,全身清除率降低超过50%。另一方面,作为尿液排泄类型的FD-4在37℃和32℃之间的静脉药代动力学几乎没有差异。然而,在28℃时FD-4的肾清除率显著降低。因此,低温组中药物的药代动力学变化可能因消除过程而异。